Skip to main content

Table 1 Baseline characteristics of adult persons with complete SVR data treated with SOF-based regimens by HCV genotypes within the national hepatitis C elimination program, April 28, 2015 – October 31, 2018

From: Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia

Characteristic

TOTAL

Genotype 1

Genotype 2

Genotype 3

Genotype 4

n

%

n

%

n

%

n

%

n

%

Age category, n (%)

 18–45

1635

32.2

386

22.4

299

28.6

948

41.1

2

66.7

 45–60

2838

55.9

944

54.8

630

60.2

1264

54.8

.

.

 60+

606

11.9

394

22.9

118

11.3

93

4.0

1

33.3

Gender, n (%)

 Female

698

13.7

486

28.2

101

9.6

110

4.8

1

33.3

 Male

4381

86.3

1238

71.8

946

90.4

2195

95.2

2

66.7

HCV RNA categories, n (%)

 < 800,000 IU/mL

2922

57.7

901

52.5

625

59.8

1393

60.5

3

100.0

 ≥ 800,000 IU/mL

2145

42.3

816

47.5

420

40.2

909

39.5

.

.

FIB-4 Test

 < 1.45

200

5.7

65

6.0

51

7.0

84

5.0

.

.

 1.45–3.25

1763

50.2

491

45.0

403

55.1

868

51.5

1

50.0

 > 3.25

1546

44.1

535

49.0

277

37.9

733

43.5

1

50.0

Metavir score

 < F4

2021

42.1

676

39.8

516

50.9

827

39.6

2

66.7

 F4

2783

57.9

1021

60.2

497

49.1

1264

60.4

1

33.3

Liver function tests, n (%)

 ALT >2 X ULN

2585

51.0

731

42.5

466

44.6

1385

60.2

3

100.0

 AST >2 X ULN

2604

51.4

783

45.6

442

42.3

1376

59.8

3

100.0

 Billirubin >1.1 mg/dL

4423

87.3

1520

88.5

928

88.8

1972

85.7

3

100.0

 Albumin < 35 g/L

2001

39.5

670

39.0

469

44.9

862

37.4

.

.

 INR >1.49

687

13.6

260

15.1

132

12.6

295

12.8

.

.

Co-infections, n (%)

 HBsAg+

108

2.2

28

1.7

19

1.9

61

2.8

.

.

 HBsAg-

4777

97.8

1666

98.3

985

98.1

2123

97.2

3

100.0

Treatment regimen, n (%)

 IFN/SOF/RBV (12 wk)

2646

52.1

905

52.5

240

22.9

1500

65.1

1

33.3

 SOF/RBV (12 wk)

364

7.2

3

0.2

360

34.4

1

0

.

.

 SOF/RBV (20 wk)

395

7.8

3

0.2

392

37.4

.

.

.

.

 SOF/RBV (24 wk)

1418

27.9

695

40.3

7

0.7

714

31

2

66.7

 SOF/RBV (48 wk)

256

5

118

6.8

48

4.6

90

3.9

.

.

City of treatment site, n (%)

 Tbilisi

3800

74.8

1294

75.1

819

78.2

1684

73.1

3

100

 Kutaisi

362

7.1

148

8.6

72

6.9

142

6.2

.

.

 Batumi

501

9.9

177

10.3

67

6.4

257

11.1

.

.

 Zugdidi

328

6.5

90

5.2

81

7.7

157

6.8

.

.

 Gori

42

0.8

6

0.3

5

0.5

31

1.3

.

.

 Rustavi

40

0.8

9

0.5

3

0.3

28

1.2

.

.

 Lanchkhuti

4

0.1

.

.

.

.

4

0.2

.

.

 Gurjaani

2

0

.

.

.

.

2

0.1

.

.

  1. SOF Sofosbuvir, RBV Ribavirin, IFN Interferon